Bavarian Nordic launches Phase 1/2 study of prime/boost vaccine CV301 in colorectal and pancreatic cancers [Seeking Alpha]
BAVARIAN NORDIC R/I S/ADR (BVNRY)
NASDAQ:AMEX Investor Relations:
bavarian-nordic.com/investor.aspx
Company Research
Source: Seeking Alpha
Dosing is underway in a Phase 1/2 clinical trial evaluating Bavarian Nordic A/S's ( OTCPK:BVNKF ) CV301, combined with AstraZeneca's ( AZN ) PD-L1 inhibitor IMFINZI (durvalumab) and maintenance chemo, in patients with metastatic colorectal or pancreatic cancers. The primary objective of the first phase is to determine the recommended dose for the second phase, which will measure progression-free survival over 8.5 months and overall survival over four months. According to ClinicalTrials.gov, the estimated primary completion date is December 2021. The company says CV301 is poxvirus-based prime/boost vaccine designed to generate a robust and durable T cell response. Preclinical data showed that it upregulated PD-L1 antigen expression on tumor cells thereby potentially generating a greater response to PD-L1 inhibitor therapy. Click to subscribe to real-time analytics on AZN Now read: Politics Wants To Get Their Vote On DSUVIA » Subscribe for full text
Show less
Read more
Impact Snapshot
Event Time:
BVNRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BVNRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BVNRY alerts
High impacting BAVARIAN NORDIC R/I S/ADR news events
Weekly update
A roundup of the hottest topics
BVNRY
News
- Morris & Dickson is the First U.S. Distributor for Bavarian Nordic's JYNNEOS®, the Only FDA-approved Mpox Vaccine [Yahoo! Finance]Yahoo! Finance
- Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S. [Yahoo! Finance]Yahoo! Finance
- Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.GlobeNewswire
- Mpox cases in the US are on the rise as vaccination rates lag and new threats loom [CNN]CNN
- Mpox cases in the US are on the rise as vaccination rates lag and new threats loom [CNN]CNN